Ellen Vaughey, MD
Critical Care Medicine · Annandale, VANPI 1346257219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 292 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,045 and has fallen 99.1% since, to $19 in 2024.
Across 292 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$896
- GSK$744
- Boehringer Ingelheim$474
- Sanofi$458
- Genentech USA, Inc.$247
- Inari Medical, Inc.$243
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,44495%
- Education$2595%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $896 |
| GSK | 53 | $744 |
| Boehringer Ingelheim | 24 | $474 |
| Sanofi | 22 | $458 |
| Genentech USA, Inc. | 12 | $247 |
| Inari Medical, Inc. | 1 | $243 |
| Johnson & Johnson | 11 | $214 |
| Amgen | 10 | $199 |
| Baxter Healthcare | 8 | $199 |
| Mylan Specialty L.p. | 9 | $173 |
| Insmed, Inc. | 8 | $159 |
| Regeneron Healthcare Solutions, Inc. | 7 | $150 |
| Actelion Pharmaceuticals US, Inc. | 7 | $146 |
| Sanofi-aventis U.S. LLC | 2 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $138 |
| Grifols USA, LLC | 5 | $117 |
| CSL Behring | 2 | $110 |
| Mallinckrodt Hospital Products Inc. | 4 | $108 |
| Electromed, Inc. | 7 | $100 |
| Philips North America LLC | 5 | $93 |
| Gilead | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $59 |
| Pfizer | 4 | $57 |
| Novartis | 3 | $52 |
| United Therapeutics Corporation | 2 | $45 |
| Vapotherm Inc | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Inogen, Inc. | 2 | $37 |
| Circassia Inc. | 2 | $37 |
| Merck | 2 | $29 |
| Shionogi Inc | 1 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Pulmonx Corporation | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FlowTriever$243
- ClotTriever$243
How this compares
$5,704 in reported general payments places this provider in the 85th percentile of 174 critical care medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $126,725 |
| OfevNintedanib Esylate | 12 | $79,071 |
| Spiriva RespimatTiotropium Bromide | 70 | $46,956 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $28,463 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $26,207 |
| EliquisApixaban | 17 | $20,449 |
| Arnuity ElliptaFluticasone Furoate | 48 | $18,418 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $18,414 |
| Qvar RedihalerBeclomethasone Dipropionate | 33 | $15,033 |
| Spiriva HandihalerTiotropium Bromide | 12 | $11,987 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $10,286 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $9,045 |
| Tiotropium Bromide | 12 | $5,648 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,562 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $4,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $744 | $208,858256 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $474 | $136,313106 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $896 | $22,97543 claims |
| PfizerEliquis | $57 | $20,44917 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $12 | $15,03333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 174 critical care medicine providers in Virginia.
Other critical care medicine in Annandale
- Matthew WilliamsAnnandale$235K
- Adlah SukkarAnnandale$4K
- Thieu DoAnnandale$842
- Oksana ShlobinFalls Church$375K
- Sami Abdul JawadFalls Church$193K
- Rajiv MalhotraRichmond$187K
- Thomas BouderWinchester$163K
- Christopher KingFalls Church$131K
- Rohit GoyalFredericksburg$95K
- Robert ThieleCharlottesville$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.